Investor Summary

Andrew Oskoui, CFA, serves as portfolio manager and principal of Blue Tower Asset Management, having passed all three CFA levels on his first attempt. He holds a Bachelor of Science in Biomedical Engineering from Washington University in St. Louis and a Master's Degree in Chemistry from the University of Wisconsin-Madison. His investment experience includes research at YCG and managing an equity strategy for Allometric Research & Management. Prior to finance, Andrew led materials science research for Halcyon Molecular (a Founder's Fund portfolio company) and researched nanoparticle drug delivery for cancer therapies as an engineer for Covidien. Andrew supervises all firm activities and maintains the firm's independent, fee-only structure without control by large national firms.

Read More

Fund Strategy

Blue Tower Asset Management integrates quantitative analytic technology with traditional value investing principles, applying advanced analytics to classic value investing concepts rooted in Graham and Dodd's 1934 work Security Analysis. The firm's proprietary computer algorithms analyze extensive SEC filings to detect investment signals including improvements in operating margins, stock buybacks, executive purchases, and companies becoming less capital intensive. Blue Tower seeks investments in good businesses capable of growth with high return on invested capital, economic moats that preserve business quality, and good management making capital allocation decisions aligned with investors. The flagship Blue Tower Global Value strategy invests across all market caps, industries, and geographies focusing on 15-25 securities.

Read More

FUND PERFORMANCE AS OF 31st December 2025

ANNUALIZED SINCE INCEPTION QUARTERLY YTD
- 13.2% 53.1%
2025 2024
53.1% 22.3%